ScholarIQanswers from OpenAlex & ORCID
Merrick I. Ross
ResearcherPublications, citations & collaboration network
Merrick I. Ross is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Merrick I. Ross have?
ScholarIQindexed works
Merrick I. Ross has 620 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Merrick I. Ross have?
ScholarIQcitation count
Merrick I. Ross has 58,500 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Merrick I. Ross?
ScholarIQh-index
Merrick I. Ross has an h-index of 112 in OpenAlex.
What is the i10-index of Merrick I. Ross?
ScholarIQi10-index
Merrick I. Ross has an i10-index of 357 in OpenAlex.
What is the ORCID of Merrick I. Ross?
ScholarIQorcid
The ORCID for Merrick I. Ross is on the source record.
What is the OpenAlex record for Merrick I. Ross?
ScholarIQopenalex
The OpenAlex for Merrick I. Ross is on the source record.
What are the most-cited papers on Merrick I. Ross?
ScholarIQmost cited works
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Michael B. Atkins, David R. Byrd, Antônio C. Buzaid, Alistair J. Cochran, Daniel G. Coit, Shouluan Ding, Alexander M.M. Eggermont, Keith T. Flaherty, Phyllis A. Gimotty, John M. Kirkwood, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Arthur J. Sober, Vernon K. Sondak
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch, Antônio C. Buzaid, Seng‐Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan N. Houghton, John M. Kirkwood, Kelly M. McMasters, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, John A. Thompson, John F. Thompson
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald, John F. Thompson, Douglas S. Reintgen, Natale Cascinelli, Marshall M. Urist, Kelly M. McMasters, Merrick I. Ross, John M. Kirkwood, Michael B. Atkins, John A. Thompson, Daniel G. Coit, David R. Byrd, Renée A. Desmond, Yuting Zhang, Ping‐Yu Liu, Gary H. Lyman, Aberto Morabito
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
Henry M. Kuerer, Lisa A. Newman, Terry L. Smith, Fred C. Ames, Kelly K. Hunt, Kapil Dhingra, Richard L. Theriault, Gurpreet Singh, Susan M. Binkley, Nour Sneige, Thomas A. Buchholz, Merrick I. Ross, Marsha D. McNeese, Aman U. Buzdar, Gabriel N. Hortobágyi, S. Eva Singletary
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom, Siwen Hu‐Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach‐Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari Kendra, Richard C. Wu, Craig Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas